Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 2Colonic Neoplasms 2Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Liver, Cancer of, Primary Resectable 1Inoperable Esophageal Cancer Stage I-III 1Hepatocellular Carcinoma Resectable 1Head and Neck Squamous Cell Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Cancer Metastatic 1Colon Cancer Liver Metastasis 1Carcinoma, Hepatocellular 1Advanced Metastatic Colorectal Cancer 1Advanced Gastric Cancer 1Advanced Colorectal Carcinoma 1Advanced Colorectal Cancer 1

Interventions

surufatinib 2regorafenib 2Oxaliplatin 2Irinotecan 2Fluorouracil 2Bevacizumab 2raltitrexed 1nimotuzumab 1endostar protein 1aflibercept 1Folfox protocol 1Drug Therapy 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Colorectal Cancer × raltitrexed × Clear all
NCT03126071 2021-08-30

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡